Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind active-controlled study of levomilnacipran extended-release capsules in adults with major depressive disorder
CTR20243567Phase 3Completed
- Sponsor
- Zhejiang Huahai Pharmaceutical Co., Ltd.
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of levomilnacipran in major depressive disorder (MDD) (2 arms), sponsored by Zhejiang Huahai Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in HAMD-17 total score at week 8. Started Sep 2024; status: completed.
02
Drugs
levomilnacipran
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20243567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243567.